Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Maternal blood test reveals prenatal methylation clues linked to autism risk

25

Jun 2026

Maternal blood test reveals prenatal methylation clues linked to autism risk

Researchers found that maternal plasma cell-free DNA methylation patterns in late pregnancy were associated with later autism diagnosis and maternal obesity in a high-likelihood ASD cohort. The findings suggest cfDNA may offer a minimally invasive way to study prenatal epigenetic changes linked to neurodevelopmental risk, but larger validation studies are needed.

Gene linked to lower BMI points researchers toward a new obesity target

25

Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

US study shows updated COVID vaccines cut hospitalization odds by 55%

24

Jun 2026

US study shows updated COVID vaccines cut hospitalization odds by 55%

The 2025-2026 COVID-19 vaccines were associated with 50% estimated effectiveness against COVID-19-associated emergency department and urgent care encounters among immunocompetent US adults. They were also linked to an estimated 55% effectiveness against COVID-19-associated hospitalization, providing added protection beyond existing immunity from prior infection or vaccination.

Genetic testing could sharply increase demand for ALS specialist care

24

Jun 2026

Genetic testing could sharply increase demand for ALS specialist care

The availability of genetic testing for amyotrophic lateral sclerosis (ALS) for people with a family member diagnosed with the disease is expected to greatly increase the number of clinic visits to specialized ALS centers over the next decade, according to a study published June 24, 2026, in Neurology Genetics, an official journal of the American Academy of Neurology.

Scientists map blood chemistry links to hundreds of diseases

24

Jun 2026

Scientists map blood chemistry links to hundreds of diseases

A UK Biobank study of nearly 390,000 people mapped 251 NMR-derived plasma metabolic traits against hundreds of health traits, prevalent diseases, and future disease outcomes. The atlas revealed tens of thousands of replicated associations, showed stronger prediction for selected short-term and cardiometabolic outcomes, and identified putative causal links that may guide future precision medicine research.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.